Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
BRIEF-Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer Oct 24 (Reuters) - Amgen Inc AMGN.O:
AMGEN: NEARLY 80% OF PATIENTS ON IMDELLTRA-IMFINZI ALIVE AT ONE YEAR VERSUS 53% WITH DURVALUMAB ALONE & PROGRESSION-FREE SURVIVAL MORE THAN TRIPLED
AMGEN: GRADE 3 OR HIGHER ADVERSE EVENTS OCCURRED IN 20.9% WITH IMDELLTRA PLUS IMFINZI VERSUS 10.8% WITH IMFINZI ALONE
AMGEN: IMDELLTRA IN COMBINATION WITH IMFINZI REDUCED RISK OF DEATH BY 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
AMGEN: SAFETY PROFILE OF IMDELLTRA IN COMBINATION WITH DURVALUMAB CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES
AMGEN: IMDELLTRA PLUS DURVALUMAB EXTENDS MEDIAN OVERALL SURVIVAL TO 21.1 MONTHS VERSUS 12.7 MONTHS WITH DURVALUMAB ALONE
Source text: https://tinyurl.com/ye2yvf5k
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally